Study of TST002 injection for osteoporosis in postmenopausal women
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This study tests an investigational injection called TST002 to see if it can help strengthen bones in postmenopausal women with osteoporosis or low bone mass. It may help reduce the risk of fractures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 45 to 80 years.
- You have gone through menopause at least 2 years ago (no menstrual period for 12 consecutive months).
- Your bone density is low (T-score below -2.0) at the spine or hip, or you have had a fragility fracture with low bone density (T-score below -1.0).
- Your body mass index (BMI) is between 18 and 30, and you weigh at least 45 kg (about 99 lbs).
- You can walk freely and are willing to complete all study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving zoledronic acid (a bone-strengthening infusion) right after stopping denosumab can help prevent bone loss in women with post-menopausal osteoporosis. It may be a good option if you have finished at least 2 years of denosumab and your doctor says it's safe to stop.
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
This study compares two treatment plans for women with osteoporosis to see which one improves hip bone density more. Participants will either get two medications in sequence (romosozumab followed by denosumab) or one medication (zoledronic acid), both given as injections or infusions. The goal is to find a treatment that reduces fracture risk.
This study tests whether denosumab, a medication given as an injection, can help prevent broken bones in people with type 2 diabetes who are at high risk for fractures. It aims to see if this treatment can strengthen bones and reduce fracture risk.
This study tests whether denosumab, a medication that strengthens bones, can also improve muscle strength and insulin sensitivity in postmenopausal women with type 2 diabetes who take metformin.
This study tests a new form of calcium (amorphous calcium carbonate) to see if it can improve bone density in postmenopausal women with osteoporosis. It may offer an alternative for women who cannot or choose not to take other osteoporosis medications.
Hear when a new Postmenopausal Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.